Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR et al..
2021.
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.. Nat Immunol. 22(2):240-253.
Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S et al..
2021.
The spatial landscape of lung pathology during COVID-19 progression.. Nature. 593(7860):564-569.
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U et al..
2021.
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.. J Clin Oncol. 39(14):1553-1562.
Aguiar-Pulido V, Wolujewicz P, Martinez-Fundichely A, Elhaik E, Thareja G, Aleem AAbdel, Chalhoub N, Cuykendall T, Al-Zamer J, Lei Y et al..
2021.
Systems biology analysis of human genomes points to key pathways conferring spina bifida risk.. Proc Natl Acad Sci U S A. 118(51)
Vitale I, Yamazaki T, Wennerberg E, Sveinbjørnsson B, Rekdal Ø, Demaria S, Galluzzi L.
2021.
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.. Trends Cancer. 7(6):557-572.
Buqué A, Galluzzi L, Montrose DC.
2021.
Targeting Serine in Cancer: Is Two Better Than One? Trends Cancer. 7(8):668-670.
Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan LB, De Leon JPauline, Croyle JA, Kaner J et al..
2021.
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. NPJ Precis Oncol. 5(1):44.
Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D et al..
2021.
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.. Oncoimmunology. 10(1):1889822.
Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG.
2021.
Trial watch: intratumoral immunotherapy.. Oncoimmunology. 10(1):1984677.
Galassi C, Vitale I, Galluzzi L.
2021.
Using epigenetic modifiers to target cancer stem cell immunoevasion.. Cancer Cell. 39(12):1573-1575.